CN112040949A - 降钙素基因相关肽(cgrp)拮抗剂抗体 - Google Patents

降钙素基因相关肽(cgrp)拮抗剂抗体 Download PDF

Info

Publication number
CN112040949A
CN112040949A CN201980027708.7A CN201980027708A CN112040949A CN 112040949 A CN112040949 A CN 112040949A CN 201980027708 A CN201980027708 A CN 201980027708A CN 112040949 A CN112040949 A CN 112040949A
Authority
CN
China
Prior art keywords
seq
antibody
sequence
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980027708.7A
Other languages
English (en)
Chinese (zh)
Inventor
弗兰克·J·卡尔佐内
约翰·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remd Biotherapeutics Inc
Original Assignee
Remd Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remd Biotherapeutics Inc filed Critical Remd Biotherapeutics Inc
Publication of CN112040949A publication Critical patent/CN112040949A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980027708.7A 2018-02-23 2019-02-23 降钙素基因相关肽(cgrp)拮抗剂抗体 Pending CN112040949A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862634643P 2018-02-23 2018-02-23
US62/634,643 2018-02-23
PCT/US2019/019319 WO2019165326A1 (en) 2018-02-23 2019-02-23 Calcitonin gene-related peptide (cgrp) antagonist antibodies

Publications (1)

Publication Number Publication Date
CN112040949A true CN112040949A (zh) 2020-12-04

Family

ID=67688456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980027708.7A Pending CN112040949A (zh) 2018-02-23 2019-02-23 降钙素基因相关肽(cgrp)拮抗剂抗体

Country Status (5)

Country Link
US (1) US11629184B2 (enExample)
EP (1) EP3755327A4 (enExample)
JP (1) JP2021518748A (enExample)
CN (1) CN112040949A (enExample)
WO (1) WO2019165326A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023051786A1 (zh) * 2021-09-30 2023-04-06 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途
CN117482233A (zh) * 2023-11-01 2024-02-02 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) Cgrp作为治疗靶点在筛选、开发治疗角膜损伤和神经再生药物中的应用
WO2024032750A1 (zh) * 2022-08-11 2024-02-15 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途
CN118271438A (zh) * 2024-05-27 2024-07-02 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途
WO2026098547A1 (zh) * 2024-11-08 2026-05-15 湖北生物医药产业技术研究院有限公司 一种靶向cgrp的抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101309704A (zh) * 2005-11-14 2008-11-19 礼纳特神经系统科学公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
CN103037900A (zh) * 2010-02-24 2013-04-10 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CN107108741A (zh) * 2014-09-30 2017-08-29 德国公共权益癌症研究中心基金会 与l1cam（cd171）结合的结合分子，特别是抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
KR20100115340A (ko) * 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
EP2516470B1 (en) * 2009-12-24 2018-02-07 Biosceptre (Aust) Pty Ltd Antibodies to non-functional oligomeric p2x7 receptors
PT3495392T (pt) * 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
EP2906596B1 (en) * 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
WO2015199618A1 (en) * 2014-06-24 2015-12-30 National University Of Singapore Epstein-barr virus lmp2 specific antibody and uses thereof
MX2018014950A (es) 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101309704A (zh) * 2005-11-14 2008-11-19 礼纳特神经系统科学公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
CN103037900A (zh) * 2010-02-24 2013-04-10 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CN107108741A (zh) * 2014-09-30 2017-08-29 德国公共权益癌症研究中心基金会 与l1cam（cd171）结合的结合分子，特别是抗体

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023051786A1 (zh) * 2021-09-30 2023-04-06 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途
WO2024032750A1 (zh) * 2022-08-11 2024-02-15 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途
CN117482233A (zh) * 2023-11-01 2024-02-02 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) Cgrp作为治疗靶点在筛选、开发治疗角膜损伤和神经再生药物中的应用
CN118271438A (zh) * 2024-05-27 2024-07-02 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途
WO2026098547A1 (zh) * 2024-11-08 2026-05-15 湖北生物医药产业技术研究院有限公司 一种靶向cgrp的抗体及其应用

Also Published As

Publication number Publication date
US20200407433A1 (en) 2020-12-31
WO2019165326A1 (en) 2019-08-29
EP3755327A1 (en) 2020-12-30
EP3755327A4 (en) 2021-11-24
US11629184B2 (en) 2023-04-18
JP2021518748A (ja) 2021-08-05

Similar Documents

Publication Publication Date Title
CN110337448B (zh) 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法
JP7165995B2 (ja) 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療
KR102536145B1 (ko) 항-pd-1 항체 및 이의 용도
JP5832435B2 (ja) ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体
US11629184B2 (en) Calcitonin gene-related peptide (CGRP) antagonist antibodies
US11242398B2 (en) Anti-OX40 antibodies and methods of activating OX40
KR20150002894A (ko) ｐＨ 의존성 항원 결합을 갖는 항체
TW202144428A (zh) 抗ｔｉｇｉｔ的抗體、其製備方法和應用
US12617857B2 (en) Chemokine receptor 4 (CXCR4) antagonist antibodies
JP7122758B2 (ja) プログラム死－１（ｐｄ－１）に結合する抗体を使用する免疫療法
TW201206466A (en) Antibodies with pH dependent antigen binding
JP2025534340A (ja) Ｃ－ｃケモカイン受容体タイプ８（ｃｃｒ８）アンタゴニスト抗体
CN115803062B (zh) 滋养层细胞表面抗原2(trop-2)抗体
US20210079087A1 (en) Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
HK1179279A (en) Antibodies with ph dependent antigen binding

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201204

WD01 Invention patent application deemed withdrawn after publication